7 Stocks to Get Your Heart Racing!

NASDAQ: CPRX | Catalyst Pharmaceuticals, Inc. News, Ratings, and Charts

CPRX – Catalyst Pharma is trading 51% under its fair value target…and that is the most boring stock on this list. Read on to discover the full list of 7 with up to 155% upside.

The market has been volatile and unkind to most smaller, riskier stocks. But if you are like me, there are only so many conservative large cap income stocks you can load up in your portfolio. At some point you need to get your heart racing and take a calculated risk.

If that sounds like you too, then these 7 stocks under $10 should be right up your alley.

The tamest of these stocks is Catalyst Pharma (CPRX - Get Rating) that has 51% upside to attain its fair value target set by Wall Street analysts. And sitting on top of the list with 155% upside is DURECT Corp (DRRX - Get Rating).

Let’s pull back a notch to appreciate the in-depth research process I went through to narrow down to these stocks.

  • 8,000+ US based stocks to start with.
  • 1,435 with POWR Rating of A or B. As you likely know by now, this is our proprietary rating system that is built on top of 4 different scores of a stocks attractiveness. When rolled together it points to stocks experiencing the most healthy momentum at this time and thus likely to stay on the rise.
  • 107 stocks with a price of $10 or less. Like I said it was time to get some excitement happening in our portfolios. Sure these are more speculative stocks, but I mitigate that risk by the employing other criteria to increase the odds of success. POWR Ratings is one such factor. But also the next 2 parameters are vital health checks on these stocks.
  • 83 stocks with a price target placed on them by Wall Street analysts. Meaning that 24 of them were not followed by the street. Without that important fact checking process in place, I’d rather pass on those stocks.
  • 44 stocks with consensus earnings estimates flat to higher for this year and next. This is a important health check coming out of Q2 earnings season. That’s because if estimates were heading lower…likely that negative trend would continue with much greater odds of that stock falling further in price.
  • 7 Stocks with 50% or more upside to fair value targets set by Wall Street analysts.

When you add it altogether we are talking about 7 stocks that blend healthy earnings growth + momentum + extreme value. Check them out below.

 

Company Ticker Price Target Upside % Market Cap ($mil)
   Durect Corp DRRX $1.37 $3.50 155.47% $263
   Lipocine Inc LPCN $2.40 $5.67 136.25% $60
   Compugen Ltd CGEN $3.91 $8.50 117.39% $201
   Asanko Gold Inc AKG $0.88 $1.60 81.82% $199
   Avid Bioservics CDMO $6.61 $10.50 58.85% $371
   Volitionrx Ltd VNRX $4.10 $6.25 52.44% $168
   Catalyst Pharma CPRX $6.18 $9.33 50.97% $636

What to Do Next?

I would recommend clicking on the links for the stocks that have the most appeal to you. That will take you to their respective quote pages on StockNews.com where you can find a more in-depth understanding of the stock.

I am referring to the full display of the POWR Ratings for the stock where we break it down into  4 components to appreciate the full attractiveness of the investment. a stock. That includes its Buy & Hold Grade, Trading Grade, Industry Rank and Peer Grade. Just click the ticker for each stock to discover that information and more.

One last thing…

Every day I share a limited number of top stocks through articles just like this one. However, you are cutting yourself short from all the resources of the POWR Ratings system that will help you find the best stocks to buy at any time. Not just speculative stocks like these, but large caps, high dividend, value, growth and momentum stocks.

Ratings are updated every day. And that includes updates on the stocks to sell before they harm your portfolio.

But they are only available to POWR Ratings Premium members. Gladly we have a 30 day free trial which is the best way to get started. Just click the link below to learn more and get started.

30 Day Free Trial to POWR Ratings Premium

 


CPRX shares rose $0.02 (+0.32%) in after-hours trading Wednesday. Year-to-date, CPRX has gained 226.56%, versus a 18.10% rise in the benchmark S&P 500 index during the same period.

 


About the Author: Steve Reitmeister


Steve is better known to the StockNews audience as “Reity”. Not only is he the CEO of the firm, but he also shares his 40 years of investment experience in the Reitmeister Total Return portfolio. Learn more about Reity’s background, along with links to his most recent articles and stock picks. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
CPRXGet RatingGet RatingGet Rating
Get RatingGet RatingGet Rating
CDMOGet RatingGet RatingGet Rating
CGENGet RatingGet RatingGet Rating
DRRXGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Investors Remain “Cautiously Optimistic”

The S&P 500 (SPY) has made great advances since the lows of early April. Yet seem to be stuck under resistance at 6,000. What happens next depends on tariff talks. So let’s talk about the latest news on that front.

Bull Market Til Proven Otherwise

The phrase that paid for investors in 2025 was “Bull market til proven otherwise” Steve Reitmeister explains why in his latest market update and preview of top stock picks.

Investor Alert: Mission Accomplished?

The S&P 500 (SPY) has broken out above the 200 day moving average. Does that mean that bear market fears are now over? And should investors be riding the bull to new heights? Read on for Steve Reitmeister’s answer...

Stock Market Update: It’s Complicated!

The S&P 500 (SPY) may have bounced 17% from recent lows, but the outlook for stocks from here is...in a word...COMPLICATED. Read on to get Steve Reitmeister full market outlook and trading plan for this complicated market environment.

Becoming More Bullish on Stocks, But...

Stocks are on a roll with the S&P 500 (SPY) up more than 10% from the recent lows. Before you start getting too giddy, you should read this updated market outlook and trading plan Steve Reitmeister.

Read More Stories

More Catalyst Pharmaceuticals, Inc. (CPRX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CPRX News